March 23, 2015 +44 (0)20 7025 7911 [email protected]

Clinical Development

In 2014 VIP completed a Phase I clinical trial in normal volunteers. This confirmed that, at the predicted therapeutic dose, when given by subcutaneous injection a single dose of Coversin effectively blocks the terminal complement system for at least 24 hours. A major advantage of this route is that self-injection by patients becomes possible thus avoiding the necessity of regular attendance at hospitals or doctors’ offices and the discomfort of repeated intravenous infusions of antibodies or other macromolecules. The potential improvement in patient quality of life and ancillary costs is considered by clinicians and nurses to be a major therapeutic advance.

Result of Phase 1 clinical trial showing complement inhibition after a single subcutaneous injection of Coversin

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.